Clinical trial · Interventional
Hypnosis for Patients Treated With Adjuvant Chemotherapy for Breast Cancer(HYPNOVAL)
Medical Ericksonian Hypnosis on Patients Treated With Adjuvant Chemotherapy for Breast Cancer at the ICM Val d'Aurelle - Montpellier: a Feasibility Study
NCT03250130CI-TRIAL-00046536HYPNOVALcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main objective is to assess the feasibility of an intervention based on medical Ericksonian hypnosis as a complementary therapy in patients treated with surgery after a diagnosis of breast cancer, followed by an indication of adjuvant chemotherapy and radiotherapy
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| hypnosis | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Hypnosis
- description
- The patient achieve self-hypnosis sessions in these chemotherapy treatments
- interventionNames
- Behavioral: hypnosis
Primary outcomes (1)
- measure
- proportion of patients rated as being compliant to self-hypnosis
- timeFrame
- through study completion, an average of 2 years
- description
- The main objective is to assess the feasibility of an intervention based on medical Ericksonian hypnosis as a complementary therapy in patients treated with surgery after a diagnosis of breast cancer, followed by an indication of adjuvant chemotherapy and radiotherapy. Primary endpoint is the proportion of patients rated as being compliant to self-hypnosis sessions during adjuvant chemotherapy (6 sessions). A patient is considered as compliant if it achieves at least 2/3 of the planned self-hypnosis sessions, that is, 4 of 6 planned sessions.
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * • Female, age \> 18 years-old * Without previous practice of hypnosis * Patient with diagnosis of breast cancer * Patient receiving an adjuvant chemotherapy for at least 3 months with an indication of radiotherapy after chemotherapy * Patient accepting the principle of the study with a signed written informed consent * Patient affiliated to French Social Security Exclusion Criteria: * • Male * Age \< 18 years * Patient refusing hypnosis * Pregnancy, breast-feeding, or lack of effective contraception in female patients with reproductive potential. * Patient with psychological or mental disorders under psychotropic treatments (lithium, neuroleptics) * Not ability to speak and read French, deaf and/or mute
References
Publications (0)
Data not yet available
No reference posted for this study.